Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marlou THF Janssen"'
Autor:
Marlou THF Janssen, Mark GH Thijssen, Jasenko Krdzalic, Michiel HM Gronenschild, Sofia Ramiro, César Magro-Checa, Robert BM Landewé, Rémy LM Mostard
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background CT Severity Score (CT-SS) can be used to assess the extent of severe coronavirus disease 19 (COVID-19) pneumonia. Follow-up CT-SS in patients surviving COVID-19-associated hyperinflammation and its correlation with respiratory par
Externí odkaz:
https://doaj.org/article/ccdb13dd622a4648adb608a9fdab9f6b
Publikováno v:
RMD Open, Vol 7, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/d42c86f785574f6bab4eeeb96436ba51
Publikováno v:
RMD open, 7(3):e001906. BMJ Publishing Group
RMD Open
RMD Open, Vol 7, Iss 3 (2021)
RMD Open
RMD Open, Vol 7, Iss 3 (2021)
ObjectivesTo prospectively investigate differences in medium-term patient-reported outcome measures and objective functional outcome measures, between patients receiving and those not receiving intensive short-term immunosuppressive therapy for coron
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9709dec645c8c2a7403de5fce5e5ca3e
https://pure.amc.nl/en/publications/threemonth-and-sixmonth-outcomes-of-patients-with-covid19-associated-hyperinflammation-treated-with-shortterm-immunosuppressive-therapy(d487f3f3-5092-4ba4-95e2-d70275c40331).html
https://pure.amc.nl/en/publications/threemonth-and-sixmonth-outcomes-of-patients-with-covid19-associated-hyperinflammation-treated-with-shortterm-immunosuppressive-therapy(d487f3f3-5092-4ba4-95e2-d70275c40331).html
Autor:
Dave Jw van Kraaij, Ralph Hrm Peeters, Rémy L M Mostard, Marlou Thf Janssen, Leon M. van den Toorn, Robrecht Pj van der Horst, Christel M.P. van Dongen
Publikováno v:
European Journal of Case Reports in Internal Medicine (2020)
European Journal of Case Reports in Internal Medicine
European Journal of Case Reports in Internal Medicine
COVID-19 is a novel viral disease caused by SARS-CoV-2. The mid- and long-term outcomes have not yet been determined. COVID-19 infection is increasingly being associated with systemic and multi-organ involvement, encompassing cytokine release syndrom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec285b1afd211fc2f43dfa3c5611aa95
https://www.ejcrim.com/index.php/EJCRIM/article/view/1784
https://www.ejcrim.com/index.php/EJCRIM/article/view/1784
Publikováno v:
Ann Rheum Dis
Annals of the rheumatic diseases, 80(10), 1362-1363. BMJ Publishing Group
Annals of the rheumatic diseases, 80(10), 1362-1363. BMJ Publishing Group
Several immune mechanisms resembling a hyperinflammatory state have been critically involved in the pathophysiology of severe COVID-19, motivating the use of immunomodulatory therapies in the management of these patients. Various studies have already